The Global Fairness in Drug Pricing Act: A Bill to Reduce Prescription Drug Prices

The 119th Congress passed the Global Fairness in Drug Pricing Act (HR 3493) on May 19, 2025. This bill aims to reduce prescription drug prices by aligning U.S. prices with international benchmarks.

Section 1: Short Title

This Act may be cited as the ‘‘Global Fairness in Drug Pricing Act’’.

Section 2: Drug Pricing

The bill proposes a rulemaking plan to impose most-favored-nation price targets on pharmaceutical manufacturers. This will ensure that prices for pharmaceutical products paid by patients in the United States are comparable to those in comparably developed countries.

Not later than 30 days after the date of enactment, the Secretary of Health and Human Services shall propose a rulemaking plan to impose most-favored-nation price targets on pharmaceutical manufacturers.
The Secretary shall also certify to Congress that importation under section 804(j) of the Federal Food, Drug, and Cosmetic Act will pose no risk to the health and safety of the public and will result in a significant reduction in the cost of prescription drugs for American patients.

Section 3: Enforcement Actions

The Attorney General and the Chair of the Federal Trade Commission shall undertake enforcement actions against any anticompetitive practices by pharmaceutical manufacturers, including through enforcement of sections 1 and 2 of the Sherman Act and section 5 of the Federal Trade Commission Act.

Section 4: Programs Enabling Direct-to-Consumer Purchases

The Secretary of Health and Human Services shall facilitate direct-to-consumer purchasing programs for pharmaceutical manufacturers that sell their pharmaceutical products to patients in the United States at the prices determined through the rulemaking under subsection (a).

Section 5: Study of Unreasonable or Discriminatory Behaviors

The Secretary of Commerce and the United States Trade Representative shall conduct a study to determine whether any act, policy, or practice by pharmaceutical manufacturers constitutes unreasonable or discriminatory behavior that impairs national security, forces patients in the United States to subsidize global pharmaceutical research and development, or involves suppression of drug prices in foreign markets below fair market value.

The findings of such a study shall be submitted in a report to Congress not later than 180 days after the date of the enactment of this Act.

Read more about this bill at: https://www.govinfo.gov/app/details/BILLS-119hr3493ih